1-3 of 3
Dong Li, MD
Close
Sort by
Journal Articles

Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

Lung-Ji Chang, PhD, Lujia Dong, MD, Yu-Chen Liu, MSc, Shih-Ting Tsao, MSc, Ya-Chen Li, PhD, Li Liu, MD, Zhiyong Gao, MD, Xiyou Tan, MD, Dao-Pei Lu, MD, Jian-Ping Zhang, Jing-Bo Wang, Yu-Ming Ying, MD, Le-Ping Zhang, MD, Huyong Zheng, MD PhD, Kai Wang, MD PhD, Xiao-Li Zheng, MD, Heng-Xiang Wang, MD, Xun Lai, MD, Dong Li, MD
Journal: Blood
Blood (2016) 128 (22): 587.
https://doi.org/10.1182/blood.V128.22.587.587
Published: 2016
Journal Articles

Positive Expression of MUC1 Gene Is a Poor Prognostic Factor in Acute Myelogenous Leukemia.

Ren-wei Huang, MD, Guo-wei Li, MD, Dong-ning Wang, MD, Xu-dong Li, MD, Gui-zhen Lin, MD, Dong-jun Lin, MD
Journal: Blood
Blood (2006) 108 (11): 4294.
https://doi.org/10.1182/blood.V108.11.4294.4294
Published: 2006
Journal Articles

The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT).

Elias J. Anaissie, MD, Monica L. Grazziutti, MD, Dong Li, MD, MS, Marisa H. Miceli, MD, Athanasios Fassas, MD, Raymond Thertulien, MD, PhD, Sabitha Rajan, Fariba Saghafifar, MD, Guido J. Tricot, MD, Bart Barlogie, MD
Journal: Blood
Blood (2004) 104 (11): 1159.
https://doi.org/10.1182/blood.V104.11.1159.1159
Published: 2004